Product image of Leverette (Ethinylestradiol, Levonorgestrel | Lactose) supplied by GNH India

Leverette

Active Ingredient:
Ethinylestradiol, Levonorgestrel | Lactose
Origin:
EU

Leverette (Ethinylestradiol, Levonorgestrel | Lactose)

Ethinylestradiol and Levonorgestrel, the active ingredients in Leverette, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus and endometrial lining.

GNH India supplies Leverette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Uab Exeltis Baltics

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Leverette, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent unintended pregnancy.

  • Prevention of pregnancy: provides reliable contraception for women of childbearing age.
  • Menstrual cycle regulation: helps to achieve more predictable menstrual bleeding patterns.
  • Management of dysmenorrhea: reduces menstrual pain associated with ovulatory cycles.

How It Works

  • Ethinylestradiol and levonorgestrel bind to estrogen and progesterone receptors, respectively, suppressing the hypothalamic‑pituitary‑ovarian axis. This inhibition prevents the mid‑cycle luteinising hormone surge, thereby blocking ovulation. The progestogenic component also thickens cervical mucus and induces endometrial changes that are unfavorable for implantation.

Side Effects

Leverette may cause a range of adverse reactions.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Breast tenderness: temporary swelling or discomfort.
  • Headache: occasional mild to moderate pain.
  • Spotting or breakthrough bleeding: irregular light bleeding.
  • Mood changes: mild fluctuations in mood.
  • Weight gain: slight increase in body weight.

Serious or Rare Side Effects

  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Severe hypertension: sudden increase in blood pressure.
  • Hepatic adenoma: benign liver tumor.
  • Allergic reaction: rash, itching, or swelling.
  • Visual disturbances: blurred vision or loss of vision.
  • Stroke: rare cerebrovascular accident.

Precautions & Warnings

Before prescribing Leverette, clinicians should assess individual risk factors and counsel patients on safe use.

  • Assess thrombotic risk: evaluate personal or family history of clotting disorders.
  • Review cardiovascular status: consider hypertension, smoking, or age over 35.
  • Screen for liver disease: avoid use in active hepatic impairment.
  • Counsel on medication adherence: missed tablets reduce efficacy.
  • Discuss potential drug‑drug interactions: especially enzyme‑inducing agents.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Leverette can interact with several medicines that alter hormone levels or increase adverse event risk.

Major Interactions (Avoid)

  • Strong enzyme inducers (e.g., rifampin, carbamazepine): may reduce contraceptive effectiveness.
  • Certain antiretrovirals (e.g., protease inhibitors): can alter hormone metabolism.
  • Azole antifungals (e.g., ketoconazole): may increase hormone concentrations.

Moderate Interactions (Monitor Closely)

  • SSRIs and other antidepressants: may increase risk of bleeding.
  • St. John's wort: may decrease contraceptive efficacy.
  • Anticonvulsants with moderate inducing effect: monitor for breakthrough bleeding.

Frequently Asked Questions

Leverette is a combined oral contraceptive containing ethinyloestradiol and levonorgestrel. It is prescribed to prevent pregnancy in women of reproductive age by inhibiting ovulation, thickening cervical mucus, and altering the uterine lining to reduce the chance of implantation.

Ethinyloestradiol is a synthetic estrogen that suppresses the release of follicle‑stimulating hormone and luteinising hormone from the pituitary gland. This suppression prevents the mid‑cycle surge needed for ovulation, thereby contributing to the contraceptive effect of Leverette.

The dosage regimen for Leverette is determined by the prescribing clinician. Typically, it is taken as a daily tablet according to a specific cycle, but the exact schedule and number of tablets per pack are set by the healthcare provider based on individual patient needs.

Leverette is intended for use only when pregnancy is not present. If pregnancy occurs, the product should be discontinued. Safety during breastfeeding has not been fully established, and clinicians usually advise weighing potential risks and benefits before continuing use while nursing.

To order Leverette, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Leverette contains the same active hormone combination found in many other combined oral contraceptives, offering comparable efficacy and safety profiles. Differences may lie in tablet formulation, excipients, or brand‑specific packaging, but the core mechanism of preventing ovulation remains consistent across products.

Leverette tablets should be stored at ambient temperature below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Leverette is taken orally, usually once daily at the same time each day. The tablets are swallowed whole with water and should be started on the first day of the menstrual cycle or as directed by a healthcare professional.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe hypertension, and rare hepatic tumors. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, severe headache, or visual changes.

Leverette is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known estrogen‑dependent tumors, or those who are pregnant. It should also be avoided by individuals taking strong enzyme‑inducing medications that could reduce its effectiveness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Levonorgestrel | Lactose

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT